Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-951
- Development stage
- Preclinical
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-951 is an experimental small molecule modulator of the Adenosine receptor A3 (A3AR), currently in the preclinical stage of development by Chong Kun Dang Pharmaceutical Corp. It is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a condition characterized by liver inflammation and damage caused by fat accumulation. By targeting the A3 adenosine receptor, CKD-951 aims to modulate biological pathways involved in hepatic inflammation and fibrosis, which are hallmark features of MASH progression. As of the current reporting, it remains in the early pipeline as a new chemical entity.
02
Targets
ADORA3 (Adenosine A3 receptor)
Beyond the preview
Go deeper on CKD-951.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-951.